Niagen Bioscience (NAGE) stock surged 5.09% during Tuesday's intraday trading session, following a report that identified the company as one of the top 10 undervalued stocks in the United States based on cash flow analysis. This sudden uptick in investor interest appears to be directly linked to the stock's perceived undervaluation in the market.

According to the report, Niagen Bioscience is currently trading at $9.82, significantly below its estimated fair value of $19.02. This represents a potential discount of 48.4%, making it an attractive option for value investors. The substantial gap between the current market price and the estimated fair value suggests that the stock may have considerable room for growth, which likely triggered the buying spree observed in today's trading session.

While the broader market context includes recent retreats from record highs and investor vigilance regarding potential shifts in monetary policy, the identification of NAGE as an undervalued stock has evidently sparked interest. Investors appear to be capitalizing on this perceived market inefficiency, driving up the stock price in anticipation of future gains as the market potentially corrects this undervaluation. As always, investors are advised to conduct their own due diligence and consider their risk tolerance before making investment decisions based on such analyses.